晚期胰腺癌患者应用吉西他滨联合替吉奥治疗的临床效果评价

The clinical effect evaluation of gemcitabine combined with tegafur,gimeracil and oteracil potassium capsules treatment on the patients with advanced pancreatic cancer

目的分析晚期胰腺癌患者应用吉他西滨联合替吉奥治疗的临床效果。方法选取64例晚期胰腺癌的患者并将其按数字表法随机分为观察组和对照组，每组32例。对照组患者用吉他西滨治疗，观察组患者应用吉他西滨联合替吉奥治疗。对比两组患者的治疗效果、临床受益情况、一临床生存时间和不良反应的发生情况。结果观察组总有效率（81．25％）与对照组的（53．13％）相比明显较高，差异具有统计学意义（P〈0．05）；观察组患者不良反应发生率（62．51％）与对照组（68．76％）相比稍低，差异无统计学意义（P〉0．05）；观察组患者临床生存时间小于1个月、1～3个月的明显低于对照组，差异具有统计学意义（P〈0．05）；观察组患者临床生存时间3—6个月明显高于对照组，差异具有统计学意义（P〈0．05）；但观察组患者临床生存时间大于6个月的比率与对照组无明显差异，差异无统计学意义（P〉0．05）。观察组临床受益率（81．25％）明显高于对照组临床受益率（53．13％），差异具有统计学意义（P〈0．05）。结论晚期胰腺癌患者采用吉他西滨联合替吉奥治疗效果显著，临床受益反应提高且生存时间延长，不良反应与单用吉他西滨治疗无明显差异，安全可靠，值得在临床上推广。

Objective To analyze the clinical application effect of gemcitabine combined with tegafur,gimeracil and oteracil potassium capsules in the patients with advanced pancreatic cancer. Methods Sixty-fourcases of patients with advanced pancreatic cancer were randomly divided into the observation group and the control group,32 cases in each group. The patients of control group were given gemcitabine treatment,and the patients of the observation group were treated with gemcitabine combined with tegafur,gimeracil and oteracil potassium capsules treatment.The therapeutic effect,clinical benefit rate,clinical survival time and adverse reactions was compared between two groups. Results The total effective rate（ 81. 25%） of the observation group was significantly higher than that of the control group（ 53. 13%）,with significant difference（ P 0. 05）. The postoperative complication rate of the observation group（ 62. 51%） was less lower than the control group（ 68. 76%）,with no significant difference（ P〈0. 05）. The clinical survival time of the observation group was significantly lower than that of the control group at less than 1 months,1 ~ 3 months,with statistically significant difference（ P〈0. 05）. The clinical survival time of the observation group was significantly higher than that of the control group at 3 ~ 6 months,with statistically significant difference（ P〈0. 05）; yet the clinical survival time of the observation group was more than the control group at more than 6 months,and there was not significantly different（ P〈0. 05）. The clinical benefit rate（ 81. 25%） of the observation group was significantly higher than that of the control group（ 53. 13%）,with statistically significant difference（ P〈0. 05）. Conclusion Gemcitabine combined with tegafur,gimeracil and oteracil potassium capsules on the patients with advanced pancreatic cancer has remarkable curative effect,increase clinical benefit response and can prolong the survival time,and adverse reactions occur rate is less low. The combination use is safe and reliable and it is worthy in clinical promotion.